Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;30(3):1-3.

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis

Mohamad R Taha  1 , Stephen K Tyring  2   3
Affiliations
  • PMID: 40403168
Free article
Review

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis

Mohamad R Taha et al. Skin Therapy Lett. 2025 May.
Free article

Abstract

Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.

Keywords: atopic dermatitis; interleukin-31; nemolizumab-ilto; prurigo nodularis; pruritus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

MeSH terms

LinkOut - more resources